EXPERT PERSPECTIVES.
- Resource Type
- Opinion
- Authors
- Chia, Yee H.; Ma, Cynthia X.; Ellis, Matthew J.
- Source
- Breast Diseases: A Year Book Quarterly; Jan-Mar2010, Vol. 20 Issue 4, p355-357, 3p, 1 Diagram, 1 Chart
- Subject
- CANCER treatment
BREAST cancer
TAMOXIFEN
AROMATASE inhibitors
ADJUVANT treatment of cancer
- Language
- ISSN
- 1043321X
The article focuses on the efficacy of neoadjuvant endocrine therapy for the treatment of breast cancer. The use of tamoxifen as a primary treatment approach in older women was abandoned after surgery was shown to be important for an optimal outcome. Based on the result of a meta-analysis, aromatase inhibitor (AI) letrozole is more effective that tamoxifen. The authors note that adjuvant chemotherapy should not be administered to patients in the pathologic stage 1/0, preoperative endocrine prognostic index (PEPI) 0.